Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 1; peer review: 2 approved]
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison o...
Main Authors: | Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2020-02-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/9-129/v1 |
Similar Items
-
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 2; peer review: 3 approved]
by: Yu Wai Chen, et al.
Published: (2020-04-01) -
A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors
by: Seri Jo, et al.
Published: (2022-06-01) -
Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
by: Yi Kuang, et al.
Published: (2023-04-01) -
TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19
by: Mohammad Azam Ansari, et al.
Published: (2020-11-01) -
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
by: Vicky Mody, et al.
Published: (2021-01-01)